Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise

Merck shares have rebounded 55% over the past year as investors look past Keytruda’s 2028 patent expiry and focus on a post-Keytruda pipeline strategy. The article cites acquisitions and partnerships with Terns Pharma, Cidara, Verona, and Daiichi Sankyo as potential offsets to Keytruda declines, with roughly $17.35bn in new product revenue projected by 2030. A potential $350bn valuation implies about 15% upside from current levels.

Analysis

The market is starting to price MRK less like a single-asset patent cliff story and more like a late-cycle platform with optionality. That re-rating is plausible, but the key second-order effect is capital allocation: every dollar spent on bolt-ons now is effectively buying time until the 2028 exclusivity overhang, so the next 12-24 months will be judged on pipeline conversion speed rather than headline revenue growth. If management can show one or two externally sourced assets maturing into credible 2028-2030 offsets, the multiple can compress the patent-discount the market has embedded for years.

The biggest beneficiaries are likely the smaller biotech partners and acquisition targets that can de-risk programs with non-dilutive pharma capital; the losers are internal R&D-only peers that lack balance-sheet flexibility and will look slower in a world where big pharma is willing to “rent” innovation. A less obvious knock-on is competitive pressure on other large-cap pharmas with similar single-product concentration: MRK’s visible transition path may force the market to re-underwrite BMY, PFE, and ABBV on a stricter post-patent framework, especially if they cannot show comparable replacement pipelines.

The contrarian risk is that the current optimism is front-running execution that still has multiple binary hurdles: integration, clinical readouts, and eventual commercialization. The time horizon matters — near-term catalysts are likely sentiment-driven and could persist for months, but the real test is 2026-2028 when investors need evidence that replacement revenue is not just a spreadsheet construct. Any negative readout or slower-than-expected take-up in the new assets would likely hit harder than the 15% upside case because the stock has already de-risked meaningfully.

Consensus may be underestimating how much of MRK’s rerating depends on the quality of the replacement mix, not just the quantity. If the new products skew to narrower indications or more competitive pricing environments, the market may eventually haircut the optimistic 2030 revenue bridge. Conversely, if management keeps converting partnerships into de-risked clinical assets, the stock can keep working even before the patent-expiry date becomes acute.

Key Decisions for Investors

• Stay long MRK on a 6-12 month horizon, but treat it as a catalyst-driven hold rather than a passive core — upside is attractive into pipeline milestones, while the thesis breaks if replacement assets fail to de-risk by 2026.
• Buy MRK call spreads (e.g., 6-12 month tenor) to express the rerating thesis with limited downside; the setup favors convexity because much of the patent cliff fear is already discounted, but the upside is capped if execution is merely average.
• Pair trade: long MRK / short a slower-transition large-cap pharma with a similar patent-overhang profile if one is trading at a richer multiple; the relative trade isolates execution quality rather than sector beta.
• Use any 8-10% post-rally pullback in MRK to add exposure; the market is likely to overreact to ordinary clinical noise, creating better entry points than chasing strength after partnership headlines.
• If MRK underperforms on a major readout or strategic update, cut quickly — the thesis is path-dependent, and failure to show pipeline conversion by the next 2-4 quarters would meaningfully reduce the probability of the 2030 valuation bridge.